GLAND2,950.00

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹48,604 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity8.857.639.929.92
Return on Assets7.256.228.218.21
Return on Capital Employed10.679.2211.0611.06
Return on Invested Capital7.768.5311.6812.94
Margins
EBITDA Margin23.5322.5925.3426.04
Operating Margin17.4515.8618.7518.75
Incremental Operating Margin202.1238.67
Pretax Margin19.9918.9222.7723.59
Net Income Margin13.6412.4415.9816.78
Net Income to Common Margin13.6412.4415.9816.78
FCF Margin10.579.278.358.35
Additional
Effective Tax Rate31.7934.2729.8628.86
Dvd Payout Ratio0.0047.1728.87
Sustainable Growth Rate8.854.037.069.92
Incremental Operating Margin %202.1238.6737.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.